
MXCT
MaxCyte Inc.
Company Overview
| Mkt Cap | $162.04M | Price | $0.71 |
| Volume | 620.90K | Change | +0.00% |
| P/E Ratio | -3.9 | Open | $0.70 |
| Revenue | $38.6M | Prev Close | $0.71 |
| Net Income | $-41.1M | 52W Range | $0.64 - $2.96 |
| Div Yield | N/A | Target | $4.67 |
| Overall | 46 | Value | 60 |
| Quality | 39 | Technical | 40 |
No chart data available
About MaxCyte Inc.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Latest News
MaxCyte Appoints New Chief Financial Officer Ahuja
MaxCyte Appoints New Chief Financial Officer Ahuja
MaxCyte Reports Lower 2025 Revenue, Provides 2026 Outlook
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MXCT | $0.71 | 0% | 620.90K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |